An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma

Trial Profile

An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Peregrine Ophthalmic
  • Most Recent Events

    • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 20 Apr 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.
    • 20 Apr 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top